Literature DB >> 15902426

Investigation of the role of hyperbaric oxygen therapy in cisplatin-induced nephrotoxicity in rats.

Enes Murat Atasoyu1, Senol Yildiz, Oguz Bilgi, Hakan Cermik, Rifki Evrenkaya, Samil Aktas, Mustafa Gültepe, E Gökhan Kandemir.   

Abstract

Cisplatin (CP) is an effective chemotherapeutic agent used in the treatment of a variety of solid tumours. The most frequently observed side-effect of the use of CP is nephrotoxicity. Recently, evidence has been demonstrated that reactive oxygen species forming in the tubular epithelium play an important role in CP-linked nephrotoxicity. The aim of the study was to observe the effect of hyperbaric oxygen (HBO) therapy on CP nephrotoxicity, a subject which has not been studied previously. Wistar rats were treated with CP (a single intraperitoneal (IP) dose of 0.6 mg/100 g) alone and in combination with HBO (60 min every day for seven days at 2.5 x atmospheric pressure). Effects of the treatment on renal function and histology were determined. In analyses at the end of the study it was observed that serum urea, creatinine, and daily urinary protein excretion levels of the CP group were higher than at the start of the study, and that the creatinine clearance level had fallen (P < 0.05). There was no significant difference between the CP+HBO group and HBO group serum urea, creatinine, creatinine clearance, and daily urinary protein excretion levels at the beginning and end of the study (P > 0.05). Histopathological examination showed that the necrosis score in the proximal tubule epithelial cells and average apoptitic cell numbers in the CP group were higher than those in the CP+HBO and HBO groups (P < 0.05). There was no statistical difference between the CP+HBO group and the HBO group in terms of necrosis score in the proximal tubule epithelial cells and the percentage of distal tubules containing hyaline casts in the lumen. In conclusion, in this study it was observed that in experimental study of CP nephrotoxicity the synchronous application of HBO therapy with CP prevents kidney damage.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15902426     DOI: 10.1007/s00204-004-0627-3

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  6 in total

1.  Preventive effects of hyperbaric oxygen treatment on glycerol-induced myoglobinuric acute renal failure in rats.

Authors:  Suleyman Ayvaz; Burhan Aksu; Mehmet Kanter; Hafize Uzun; Mustafa Erboga; Alkin Colak; Umit Nusret Basaran; Mehmet Pul
Journal:  J Mol Histol       Date:  2012-02-07       Impact factor: 2.611

Review 2.  Metabolomics as an extension of proteomic analysis: study of acute kidney injury.

Authors:  Didier Portilla; Laura Schnackenberg; Richard D Beger
Journal:  Semin Nephrol       Date:  2007-11       Impact factor: 5.299

Review 3.  Chemotherapy-associated renal dysfunction.

Authors:  Vaibhav Sahni; Devasmita Choudhury; Ziauddin Ahmed
Journal:  Nat Rev Nephrol       Date:  2009-06-30       Impact factor: 28.314

4.  The relationship between N-acetylcysteine, hyperbaric oxygen, and inflammation in a rat model of acetaminophen-induced nephrotoxicity.

Authors:  Hakan Cermik; Mine Yavuz Taslipinar; Ibrahim Aydin; Mehmet Agilli; Fevzi Nuri Aydin; Fatma Ucar; Bilal Firat Alp; Mehmet Toygar; Esin Ozkan; Ertan Altayli; Tuncer Cayci
Journal:  Inflammation       Date:  2013-10       Impact factor: 4.092

5.  Anti-inflammatory and anti-apoptotic effects of hyperbaric oxygen preconditioning in a rat model of cisplatin-induced peripheral neuropathy.

Authors:  Emad Khademi; Vahid Pirhajati Mahabadi; Hassan Ahmadvand; Esmaeil Akbari; Ali Reza Khalatbary
Journal:  Iran J Basic Med Sci       Date:  2020-03       Impact factor: 2.699

6.  Effects of pretreatment with single-dose or intermittent oxygen on Cisplatin-induced nephrotoxicity in rats.

Authors:  Bahram Rasoulian; Ayat Kaeidi; Soheila Pourkhodadad; Omid Dezfoulian; Maryam Rezaei; Hannaneh Wahhabaghai; Masoud Alirezaei
Journal:  Nephrourol Mon       Date:  2014-09-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.